Diffuse Large B-Cell Lymphoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Diffuse Large B-Cell Lymphoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 4 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092PFS-INV | Phase 3 | Active, not recruiting | 2026-09-01 | in 12 d | 2026-04-01 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-19 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251Part 1: Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-07-02 |
| KPTI | Karyopharm Therapeutics Inc | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014 | Phase 2/3 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-07-02 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Diffuse Large B-Cell Lymphoma
most recently updated first77 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | $545.6B | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | 2021-09-13 | Nov 2026 | ≤ 102 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLNCT05952024Percentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs) | Phase 2 | Recruiting | Drug: Acalabrutinib · Biological: Rituximab | Diffuse Large B-Cell Lymphoma | 80 | 2024-07-16 | 2029-04-22 | in 976 d | 2026-08-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaNCT06091865Incidence of Dose Limiting Toxicities (DLTs) | Phase 3 | Recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | 2023-12-13 | 2028-03-30 | in 588 d | 2026-08-06 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886observationalPrimary Outcome - Blood and Residual Tissue Specimen Collection from 160 Completed Participants for Blood-Based Cancer Monitoring and Detection and Cancer Assay Development. | — | Recruiting | — | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Transformed Follicular Lymphoma, Follicular Lymphoma Grade 3B, Follicular Lymphoma, Anaplastic Large Cell Lymphoma | 200 | 2026-07-27 | Apr 2032 | ≤ 2,080 d | 2026-08-06 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558Event free survival | Phase 3 | Recruiting | Biological: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel | Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | 400 | 2026-01-12 | Dec 2029 | ≤ 1,229 d | 2026-08-04 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLNCT04404283Overall survival (OS) | Phase 3 | Active, not recruiting | Drug: Brentuximab vedotin, Rituximab, Lenalidomide · Other: Placebo | Diffuse Large B-cell Lymphoma | 239 | 2020-08-20 | 2026-01-23actual | — | 2026-07-22 |
| ADCT | ADC Therapeutics S.A. | $131M | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)NCT05660395Number of Participants with Moderate or Severe Hepatic Impairment Who Experience a Dose-Limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: This decision to close the study was made following interactions with regulatory authorities and in consideration of the challenges associated with this patient population. No safety information contributed to this decision. | Drug: Loncastuximab Tesirine | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | 5 | 2023-07-28 | 2026-06-25actual | — | 2026-07-20 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589Part 1: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns. | Drug: BGB-21447 | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma | 51 | 2023-06-20 | 2026-06-08actual | — | 2026-07-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328Phase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199 | Phase 1 | Recruiting | Drug: LY4152199 - IV | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell | 215 | 2026-05-28 | Apr 2027 | ≤ 253 d | 2026-07-10 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersNCT06120504Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations | Drug: PF-08046045 | Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | 22 | 2024-02-29 | 2025-12-10actual | — | 2026-07-06 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersNCT06254495Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns | Drug: PF-08046044/SGN-35C | Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic | 58 | 2024-05-28 | 2026-04-13actual | — | 2026-07-06 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251Part 1: Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Selinexor, Selinexor, Selinexor | Diffuse Large B-cell Lymphoma | 244 | Nov 2014 | Dec 2026 | ≤ 133 d | 2026-07-02 |
| KPTI | Karyopharm Therapeutics Inc | $44M | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014 | Phase 2/3 | Active, not recruiting | Drug: Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Relapsed/Refractory Diffuse Large B-cell Lymphoma | 501 | 2020-09-03 | Dec 2026 | ≤ 133 d | 2026-07-02 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | 572 | 2022-04-13 | Jan 2027 | ≤ 164 d | 2026-07-02 |
| AZN | AstraZeneca | — | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaNCT04594642Incidence of subjects with Dose-limiting toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: AZD0486 IV | B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma | 226 | 2021-03-02 | 2028-06-19 | in 669 d | 2026-06-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487Part A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalation | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046032, Sasanlimab | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer | 6 | 2025-05-08 | 2026-04-23actual | — | 2026-05-08 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.NCT05896163Phase 1b: Number of participants with Dose limiting toxicities (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities. | Drug: maplirpacept (PF-07901801), Glofitamab, Obinutuzumab | Diffuse Large B-Cell Lymphoma | 40 | 2023-08-30 | 2026-04-09actual | — | 2026-05-06 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)NCT05429268Overall Response Rate (ORR) | Phase 3 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide | Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | 82 | 2022-12-23 | 2026-03-30actual | — | 2026-05-05 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsNCT05618028Number of Participants With Adverse Events (AE) | Phase 1 | Active, not recruiting | Drug: ABBV-525 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma | 78 | 2023-04-04 | Jul 2029 | ≤ 1,076 d | 2026-05-04 |
| ADCT | ADC Therapeutics S.A. | $131M | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT04384484Progression-free Survival (PFS) | Phase 3 | Active, not recruiting | Drug: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 440 | 2020-09-16 | 2026-03-31actual | — | 2026-04-28 |
| INCY | Incyte Corporation | $24.7B | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCLNCT04981795observationalTreatment Patterns - Safety | — | Completed | Drug: Tafasitamab | Diffuse Large B-cell Lymphoma | 102 | 2021-09-20 | 2026-01-23actual | — | 2026-04-27 |
| INCY | Incyte Corporation | $24.7B | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092PFS-INV | Phase 3 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Diffuse Large B-cell Lymphoma | 899 | 2021-05-11 | 2026-09-01 | in 12 d | 2026-04-01 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNCT04830137Number of Participants with Protocol Specified Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: NX-2127 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL) | 248 | 2021-05-05 | May 2026 | — | 2026-03-20 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508Part A [CLOVER-1] Clinical benefit rate | Phase 2 | Active, not recruiting | Drug: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose | Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | 120 | 2017-07-26 | 2026-06-22 | — | 2026-03-18 |
| GLUE | Monte Rosa Therapeutics, Inc | $1.3B | Study of Oral MRT-2359 in Selected Cancer PatientsNCT05546268Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D | Phase 1/2 | Active, not recruiting | Drug: Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359 | NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer | 174 | 2022-10-12 | May 2026 | — | 2026-03-03 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Karyopharm Expanded Access Program for SelinexorNCT07215832expanded access | — | Available | Drug: selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma, Endometrial Cancer, Myelofibrosis, Other | — | — | — | — | 2026-03-02 |
| ABBV | AbbVie | $457.5B | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaNCT06830759observationalPercentage of Participants Achieving Overall Response (OR) | — | Recruiting | — | Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 700 | 2025-03-28 | Sep 2031 | ≤ 1,867 d | 2026-02-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)NCT04849416results2024-07-16Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee | Phase 2 | Completed | Drug: LOXO-305 | Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell | 87 | 2021-05-14 | 2023-04-10actual | — | 2026-02-06 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesNCT05665530Dose limiting toxicity (DLT) of PRT2527 | Phase 1 | Completed | Drug: PRT2527, Zanubrutinib, Venetoclax | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | 86 | 2023-09-12 | 2025-06-12actual | — | 2026-01-26 |
| INCY | Incyte Corporation | $24.7B | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsNCT05222555results2025-07-28Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide | Diffuse Large B Cell Lymphoma | 53 | 2022-07-19 | 2024-07-17actual | — | 2026-01-16 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)NCT05512390Number of Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: ABBV-319 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 154 | 2023-04-26 | Feb 2027 | ≤ 192 d | 2026-01-16 |
| SNY | Sanofi | — | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]NCT05179603results2025-10-02Complete Response Rate (CRR) | Phase 2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: THOR-707, Pembrolizumab | Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | 14 | 2021-12-07 | 2023-09-14actual | — | 2025-12-24 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Compassionate Use (CU) Program of OdronextamabNCT05619367expanded access | — | Available | Drug: Odronextamab | Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL) | — | — | — | — | 2025-12-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)NCT05169489Phase 1: Incidence of safety events including: adverse events (AEs), adverse events of special interest (AESIs), and dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: bbT369 | Diffuse Large B Cell Lymphoma (DLBCL) | 15 | 2022-01-24 | 2025-09-19actual | — | 2025-10-21 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| PFE | Pfizer | $155.3B | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaNCT05626322results2025-09-05Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns | Drug: Maplirpacept, Tafasitamab, Lenalidomide | Diffuse Large B-Cell Lymphoma | 6 | 2023-08-04 | 2024-08-12actual | — | 2025-09-05 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| INCY | Incyte Corporation | $24.7B | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)NCT02763319results2025-07-17Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population | Phase 2/3 | Completed | Drug: Rituximab (RTX), Tafasitamab, Bendamustine (BEN) | Diffuse Large B-cell Lymphoma | 453 | 2016-11-28 | 2024-06-21actual | — | 2025-07-17 |
| BMEA | Biomea Fusion Inc. | $98M | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4) | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2022-01-24 | 2025-02-13actual | — | 2025-07-03 |
| AZN | AstraZeneca | — | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLNCT05958134observationalDisease staging | — | Completed | — | Diffuse Large B Cell Lymphoma | 600 | 2023-07-15 | 2024-06-06actual | — | 2025-05-23 |
| STTK | Shattuck Labs, Inc. | $748M | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252 | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2019-03-26 | 2023-05-04actual | — | 2025-04-02 |
| BPTH | Bio-Path Holdings, Inc. | $2M | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNCT04072458Identify Dose Limiting Toxicity (DLT) of BP1002 | Phase 1 | Active, not recruiting | Drug: L-Bcl-2 antisense oligonucleotide | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL | 30 | 2020-11-05 | Apr 2025 | — | 2025-02-24 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaNCT04052061MTD or HTD and RP2D. | Phase 1 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: CD19 t-haNK | Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma | 0 | 2019-09-16 | 2021-09-18 | — | 2025-02-21 |
| NKTR | Nektar Therapeutics | $2.5B | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217Complete response (CR) rate at month 6 | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decided to end the study | Drug: NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg · Other: Placebo Comparator | Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | 15 | 2022-12-23 | 2024-05-22actual | — | 2025-02-13 |
| ADCT | ADC Therapeutics S.A. | $131M | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)NCT05144009results2025-01-30CR Rate | Phase 2 | Terminatedsponsor's stated reason: The benefit-risk profile does not support continuation of the LOTIS-9 trial. | Drug: Loncastuximab Tesirine, Rituximab | Diffuse Large B-cell Lymphoma | 41 | 2022-06-21 | 2024-01-22actual | — | 2025-01-30 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLNCT05233033To establish the Maximum Tolerated Dose (MTD) | Phase 1 | Completed | Drug: KT-413 | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation | 7 | 2022-06-13 | 2023-07-28actual | — | 2024-12-10 |
| PFE | Pfizer | $155.3B | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaNCT03530683Phase 1a: Number of adverse events (AE) by severity | Phase 1 | Terminatedsponsor's stated reason: A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product. | Drug: Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab | Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma | 189 | 2018-05-14 | 2024-07-18actual | — | 2024-09-03 |
| ADPT | Adaptive Biotechnologies | $3.9B | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyNCT05255354observationalPrimary Outcome: Predicting Progression Free Survival | — | Recruiting | Device: ClonoSEQ | Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma | 300 | 2022-06-01 | 2025-09-01 | — | 2024-08-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04806035RP2D | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: TG-1801, Ublituximab | CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL | 21 | 2021-04-28 | 2024-06-12actual | — | 2024-07-31 |
| MBIO | Mustang Bio | $14M | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.NCT05645744observationalAdverse events (AEs) | — | Terminatedsponsor's stated reason: Business Reasons | Biological: Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory | 3 | 2021-09-29 | 2024-04-12actual | — | 2024-07-22 |
| STRO | Sutro Biopharma, Inc. | $365M | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesNCT03424603Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001) | Phase 1 | Completed | Drug: STRO-001 | B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors | 70 | 2018-02-22 | 2024-02-15actual | — | 2024-06-11 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| ADCT | ADC Therapeutics S.A. | $131M | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaNCT03684694results2024-02-06Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Administrative decision | Drug: Loncastuximab Tesirine, Ibrutinib | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | 136 | 2018-12-01 | 2022-11-08actual | — | 2024-02-06 |
| CTMX | CytomX Therapeutics | $739M | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLNCT03543813The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy | Phase 1/2 | Completed | Drug: CX-2029 | Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer | 133 | 2018-06-15 | 2023-06-01actual | — | 2024-01-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT05338892observationalObjective response rate | — | Completed | Other: Non-Interventional | Diffuse Large B-Cell Lymphoma | 595 | 2022-06-22 | 2023-10-05actual | — | 2023-10-19 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)NCT02957019Number of patients with adverse events that are related to treatment and classified as DLTs for each administered dosage - phase I study | Phase 1/2 | Terminatedsponsor's stated reason: Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with innovative agents and new approved products leaddefinitive stop. | Drug: L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab | Diffuse Large B-cell Lymphoma (DLBCL) | 6 | 2013-07-31 | Sep 2023actual | — | 2023-10-10 |
| FATE | Fate Therapeutics | $307M | FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaNCT05934097Incidence of dose-limiting toxicities within each dose escalation cohort | Phase 1 | Withdrawnsponsor's stated reason: This study was withdrawn (Sponsor decision). | Drug: FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Bendamustine | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 0 | Dec 2022 | May 2026 | — | 2023-07-06 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesNCT03886831To describe dose limiting toxicities (DLT) of PRT543 | Phase 1 | Completed | Drug: PRT543 | Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia | 232 | 2019-02-11 | 2022-11-16actual | — | 2023-03-28 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaNCT02793583Overall Response Rate | Phase 2/3 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: Ublituximab, Bendamustine · Drug: Umbralisib | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma | 710 | 2016-05-25 | 2022-05-31actual | — | 2022-07-21 |
| ADCT | ADC Therapeutics S.A. | $131M | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)NCT04974996Number of Participants Who Experience Dose Limiting Toxicities (DLTs) in Part 1 | Phase 1 | Withdrawnsponsor's stated reason: Decision to not proceed with study. | Drug: Loncastuximab tesirine, Prednisone, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine | Diffuse Large B-Cell Lymphoma | 0 | 2022-02-01 | 2024-03-11 | — | 2022-03-29 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated NeurotoxicityNCT03954106results2021-12-09Incidence of CAR-T-associated Neurotoxicity of Any Grade, Defined by CTCAE v5.0 by CAR-T Day +30 | Phase 2 | Terminatedsponsor's stated reason: Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients. | Drug: Defibrotide | DLBCL, Neurotoxicity Syndromes | 25 | 2019-10-04 | 2020-09-18actual | — | 2021-12-09 |
| ABBV | AbbVie | $457.5B | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT03797261Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD) for Venetoclax + AMG 176 | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: Venetoclax, AMG 176 | Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma | 9 | 2019-03-18 | 2019-12-30actual | — | 2021-12-07 |
| ADCT | ADC Therapeutics S.A. | $131M | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaNCT03685344results2021-10-26Number of Participants With a Treatment-emergent Adverse Event (TEAE) | Phase 1 | Terminatedsponsor's stated reason: In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy. | Drug: Loncastuximab Tesirine and Durvalumab | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | 13 | 2019-02-04 | 2020-10-27actual | — | 2021-10-26 |
| GILD | Gilead Sciences | $177.9B | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLNCT01101581Safety/dose limiting toxicity | Phase 1/2 | Withdrawnsponsor's stated reason: No subjects enrolled | Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab | Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma | 0 | May 2010 | Dec 2016actual | — | 2021-08-18 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)NCT02669017results2020-04-13Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: ADCT-402 | Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma | 183 | Mar 2016 | 2019-02-21actual | — | 2021-05-19 |
| PFE | Pfizer | $155.3B | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)NCT02951156results2020-12-17Number of Participants With Dose Limiting Toxicities (DLT) | Phase 3 | Terminatedsponsor's stated reason: Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape | Biological: Avelumab, Utomilumab, Rituximab · Other: Azacitidine · Drug: Bendamustine, Gemcitabine, Oxaliplatin | Diffuse Large B-Cell Lymphoma | 29 | 2016-12-16 | 2019-12-02actual | — | 2020-12-17 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesNCT01799889results2020-09-23Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | Phase 2 | Terminatedsponsor's stated reason: Sponsor's decision to discontinue development of entospletinib. | Drug: Entospletinib MM, Entospletinib SDD | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | 326 | 2013-03-14 | 2017-09-14actual | — | 2020-11-19 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaNCT03688152Number of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: INCB053914, INCB050465 | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 9 | 2018-12-03 | 2020-09-01actual | — | 2020-11-10 |
| GILD | Gilead Sciences | $177.9B | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesNCT01796470results2020-06-02Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to safety measures. | Drug: Entospletinib, Idelalisib | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma | 66 | 2013-06-20 | Jan 2015actual | — | 2020-06-02 |
| PFE | Pfizer | $155.3B | A Study Of PF-05082566 As A Single Agent And In Combination With RituximabNCT01307267results2020-03-17Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A | Phase 1 | Completed | Drug: PF-05082566, rituximab, PF-05082566 | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma | 190 | 2011-06-21 | 2019-02-20actual | — | 2020-03-17 |
| GILD | Gilead Sciences | $177.9B | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsNCT03349346Incidence Rate of Dose Limiting Toxicities (DLTs) | Phase 1 | Withdrawnsponsor's stated reason: The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics | Drug: Idelalisib, Rituximab, Ifosfamide, Carboplatin, Etoposide | Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma | 0 | Jun 2019 | Feb 2021 | — | 2018-12-11 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced CancersNCT01563302Safety of IONIS-STAT3Rx in patients with Advanced Cancers | Phase 1/2 | Completed | Drug: IONIS-STAT3Rx | Advanced Cancers, DLBCL, Lymphoma | 64 | 2012-02-27 | 2016-03-23actual | — | 2018-06-25 |
| SNY | Sanofi | — | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PatientsNCT01472887Number of participants achieving an Objective Response Rate | Phase 2 | Completed | Drug: SAR3419 | Diffuse Large B-cell Lymphoma | 61 | Jan 2012 | Sep 2016actual | — | 2018-01-25 |
| RDHL | RedHill Biopharma Limited | — | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaNCT02229981Determine Maximum tolerated dose (MTD) of ABC294640 in patients with refractory/relapsed DLBCL or KS and determine tolerability at MTD. | Phase 1/2 | Withdrawnsponsor's stated reason: Study was discontinued due to lack of recruitment. | Drug: ABC294640 | Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | 0 | Jul 2014 | Jun 2019 | — | 2017-12-07 |
| SNY | Sanofi | — | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT01470456Number of participants achieving an Objective Response Rate | Phase 2 | Completed | Drug: SAR3419, rituximab | Diffuse Large B-Cell Lymphoma | 50 | Nov 2011 | Jul 2013actual | — | 2014-11-13 |
| AZN | AstraZeneca | — | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerNCT01499303results2014-08-22Objective Response Rate | Phase 2 | Completed | Drug: Fostamatinib | Diffuse Large B-Cell Lymphoma | 101 | Dec 2011 | Oct 2013actual | — | 2014-08-22 |
| 068270.KS | Celltrion | $30.7B | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialNCT01534949safety | Phase 1 | Terminated | Biological: rituximab | Diffuse Large B-Cell Lymphoma | 1 | Feb 2012 | Feb 2013actual | — | 2014-07-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Diffuse Large B-Cell Lymphoma is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- DLBCL
- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large B Cell Lymphoma (DLBCL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Relapsed Diffuse Large B-Cell Lymphoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Diffuse Large B-Cell Lymphoma” (a text search, wider than this page)